Aquinnah Pharmaceuticals
Biotechnology, 610 Main St, Cambridge, Massachusetts, 02139, United States, 11-50 Employees
Who is AQUINNAH PHARMACEUTICALS
Aquinnah Pharmaceuticals is focused on a new area of research and development to modulate neurodegenerative stress granules, believed to be important in the pathology of amyotrophic later...
Read More
-
Headquarters: 610 Main St, Cambridge, Massachusetts, 02139, United States
-
Date Founded: 2014
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 541714 |
Show More
Does something look wrong? Fix it. | View contact records from AQUINNAH PHARMACEUTICALS
Aquinnah Pharmaceuticals Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Aquinnah Pharmaceuticals
Answer: Aquinnah Pharmaceuticals's headquarters are located at 610 Main St, Cambridge, Massachusetts, 02139, United States
Answer: Aquinnah Pharmaceuticals's official website is https://aquinnahpharma.com
Answer: Aquinnah Pharmaceuticals's revenue is $1 Million to $5 Million
Answer: Aquinnah Pharmaceuticals's SIC: 2836
Answer: Aquinnah Pharmaceuticals's NAICS: 541714
Answer: Aquinnah Pharmaceuticals has 11-50 employees
Answer: Aquinnah Pharmaceuticals is in Biotechnology
Answer: Aquinnah Pharmaceuticals contact info: Phone number: Website: https://aquinnahpharma.com
Answer: Aquinnah Pharmaceuticals is focused on a new area of research and development to modulate neurodegenerative stress granules, believed to be important in the pathology of amyotrophic lateral sclerosis (ALS), Alzheimer's disease and other neurodegenerative diseases. The medical need for ALS is very high as there are currently no effective treatments for this devastating neurodegenerative disease. ALS progresses rapidly, eventually affecting muscles in the arms, legs, face, diaphragm, and chest. Today, approximately 60% of patients with ALS will not survive beyond three years following diagnosis, with 10% of new patients surviving at least 10 years. Aquinnah Pharmaceuticals has identified lead molecules advancing to clinical studies which are designed to prevent and potentially reverse the pathological stress granules in affected patients. In addition to their use in ALS, these compounds also show promise as a potential treatment for cognition impairment in patients with Alzheimers disease and other neurodegenerative diseases. New work published in Nature Neuroscience by co-founder Ben Wolozin, M.D.,Ph.D., has implicated stress granule disease progression with tau; which is a neuronal pathologic protein that correlates with Alzheimer's disease progression. Aquinnah is pioneering new approaches to identify small molecule drugs that modulate intracellular tau-stress granule biology, representing a new first in class treatment for Alzheimer's disease and other tauopathy diseases.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month